← Back to Search

Targeted Therapy

Investigational Agent for Cancer

Phase 2

Waitlist Available

Led By Stefan Grant, MD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from the start of treatment to date of death or date of last contact, up to 2 years

Awards & highlights

Study Summary

This trial will help determine if a simple method of selecting treatment based on identified mutations impacts progression-free survival and quality of life. Additionally, data on barriers to prescribing treatment using NGS reports will be collected.

Eligible Conditions

Cancer
Lymphoma
Genetic Mutation
Solid Tumors
Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from the start of treatment to date of death or date of last contact, up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from the start of treatment to date of death or date of last contact, up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and from the start of treatment to date of death or date of last contact, up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression Free Survival

Secondary outcome measures

Incidence of Adverse Events

Overall Survival

Response Rate

Trial Design

1Treatment groups

Experimental Treatment

Group I: Drug Administration Based on Next Gen Sequencing ReportExperimental Treatment3 Interventions

Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor

1,244 Previous Clinical Trials

1,004,761 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,692 Previous Clinical Trials

40,929,930 Total Patients Enrolled

Stefan Grant, MDPrincipal InvestigatorWake Forest University Health Sciences

2 Previous Clinical Trials

2,925 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently partaking in this clinical research?

"Affirmative. Per information obtained from clinicaltrials.gov, this medical study is searching for recruits and was initially posted on April 22nd 2020 with the latest revisions taking place on March 4th 2022. A total of 337 individuals are needed at a single location."

Answered by AI

Are recruitment options still available for this clinical trial?

"According to the data on clinicaltrials.gov, this research initiative is currently open for enrolment. The trial was initiated in April of 2020 and edited most recently in March 2022."

Answered by AI